Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs 10X Genomics Inc (TXG) Price & Performance

iShares 0 3 Month Treasury Bond ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares 0 3 Month Treasury Bond ETF vs 10X Genomics Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B), while 10X Genomics Inc trades at $79.1 (market cap $10.07B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 11.4× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and 10X Genomics Inc for 92 Days on average.

SGOVTXG
Market Cap
$114.40B$10.07B
Volume
18,879,0815,657,286
Sector
Fixed IncomeHealth
52-Week High
$100.72$97.74
52-Week Low
$100.28$11.48
Typical Hold Time
50 Days92 Days
Enterprise Value
—$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 0 3 Month Treasury Bond ETF

SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill holdings. The ETF shows bearish technical signals with 17 sell indicators versus 4 buy signals, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026. The fund continues its consistent dividend payments with recent distributions of $0.30-$0.31 per share.

SGOV provides exposure to ultra-short-term Treasury securities, offering stability amid bond market volatility. The ETF faces headwinds from rising interest rates but benefits from flight-to-quality flows. Key risks include interest rate sensitivity and potential yield compression if Fed policy shifts dovishly. Current technical weakness may present entry opportunities for income-focused investors seeking capital preservation.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SGOV
59% Buy41% Sell
Avg holding period · 50 Days
TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →